Other languages Pharmadrug Inc.

Equities

PHRX

CA71716W2040

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2024-07-12 am EDT			5-day change	1st Jan Change
0.015 ^CAD	+50.00%		0.00%	-72.73%

May. 15	PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine	MT
May. 02	PharmaDrug Announces Directorate Changes	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine	May. 15
PharmaDrug Announces Directorate Changes	May. 02
Pharmadrug Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30
Pharmadrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine	Mar. 13
PharmaDrug Inc Announces Board Changes	Feb. 27
PharmaTher Provides Update For PD-001	Feb. 21
Pharmadrug Inc. Announces Marketing and Distribution Services Agreement with Outside the Box Capital Inc	Feb. 12
Pharmadrug Inc. completed the acquisition of Securedose Synthetics Inc.	Nov. 06
Pharmadrug Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-29
PharmaDrug Inc. Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease	23-09-14
PharmaDrug Inc. Announces Board Changes	23-09-06
PharmaDrug Inc. Announces CEO Changes	23-09-06
Pharmadrug Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23
Pharmadrug Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25
Pharmadrug Inc. Appoints David Posner to Its Advisory Committee and as Consultant	23-05-23
Pharmadrug Inc. Auditor Raises 'Going Concern' Doubt	23-05-11
PharmaDrug Inc. Enters into Research Collaboration Agreement with PharmaTher Holdings Ltd	23-02-22
PharmaDrug Inc. Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer	23-02-13
PharmaDrug Advances Programs in Oncology with Filing of Patent Cooperation Treaty Application Detailing the Use of PD-001 for Treatment of Prostate Cancer	23-01-31
Pharmadrug Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Pharmadrug Inc.

Equities

PHRX

CA71716W2040

Other languages

Filters